Tuesday, October 13, 2026

AMC Stock 16% Up Today

ViaNews Editorial Team

February 15, 2023

AMC Stock 16% Up Today

(VIANEWS) - The NYSE ended the session with AMC (AMC) rising 16% to $5.22 on Wednesday while NYSE slid 0.19% to $15,994.78.

AMC's last close was $4.50, 86.89% below its 52-week high of $34.33.

About AMC

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. As of March 1, 2022, it operated approximately 950 theatres and 10,600 screens. The company was founded in 1920 and is headquartered in Leawood, Kansas.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-39.15.

Moving Average

AMC's worth is below its 50-day moving average of $5.77 and way under its 200-day moving average of $10.59.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AMC's stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

AMC's stock is valued at $5.22 at 17:04 EST, way under its 52-week high of $34.33 and way higher than its 52-week low of $3.77.

Volatility

AMC's last week, last month's, and last quarter's current intraday variation average was a negative 7.30%, a negative 0.60%, and a positive 5.60%.

AMC's highest amplitude of average volatility was 7.30% (last week), 6.94% (last month), and 5.60% (last quarter).

More news about AMC (AMC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com